| 19.23 -0.18 (-0.93%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.84  |
1-year : | 25.69 |
| Resists | First : | 20.41 |
Second : | 22 |
| Pivot price | 20.5  |
|||
| Supports | First : | 17.86 |
Second : | 14.85 |
| MAs | MA(5) : | 19.34 |
MA(20) : | 20.74 |
| MA(100) : | 18.57 |
MA(250) : | 18.58 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 10.7 |
D(3) : | 11.3 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 23.07 | Low : | 14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OCS ] has closed above bottom band by 19.1%. Bollinger Bands are 93.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.43 - 19.54 | 19.54 - 19.62 |
| Low: | 18.78 - 18.89 | 18.89 - 18.99 |
| Close: | 19.04 - 19.24 | 19.24 - 19.4 |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Fri, 07 Nov 2025
Oculis Holding AG expected to post a loss of 42 rappen a share - Earnings Preview - TradingView
Wed, 05 Nov 2025
Oculis Holding AG (OCS) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Wed, 05 Nov 2025
Oculis Holding AG Announces Participation in Upcoming Investor Conferences to Showcase Late-Stage Pipeline Developments - Quiver Quantitative
Wed, 05 Nov 2025
Oculis (NASDAQ: OCS) to share pipeline updates; 6 pivotal readouts at November events - Stock Titan
Wed, 05 Nov 2025
Oculis to Participate in Upcoming November Investor Conferences - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.133e+007 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.565e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 957 % |
| Return on Equity (ttm) | -29.8 % |
| Qtrly Rev. Growth | 764000 % |
| Gross Profit (p.s.) | 50 |
| Sales Per Share | -645.85 |
| EBITDA (p.s.) | -4.12923e+008 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.91 |
| Dividend | 0 |
| Forward Dividend | 65040 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|